Adaptive Bio

Founder‑led team with deep domain expertise. CEO and cofounder Chad Robins and CSO and cofounder Harlan Robins remain in place, and Kyle Piskel has served as CFO since 2024, steering a more disciplined operating approach. Communication of strategy and segment metrics has improved.

Execution in MRD has been strong, though the Immune Medicine path has changed (Genentech termination, Microsoft collaboration concluded), and operating leverage needs to translate into sustained positive FCF to validate long‑term stewardship quality.